BCL9

Overview

BCL9 (B-cell CLL/lymphoma 9) is a co-activator of beta-catenin-mediated transcription in the Wnt pathway. In endometrial carcinoma, BCL9 was found to participate in recurrent translocations forming predicted in-frame fusions associated with increased BCL-family expression.

Alterations observed in the corpus

  • Recurrent translocation involving BCL9 detected by low-pass WGS in 5/106 endometrial carcinoma tumors (ucec_tcga_pub); predicted in-frame fusions with increased BCL family expression. PMID:23636398

Cancer types (linked)

Co-occurrence and mutual exclusivity

  • Co-occurs with BCL2, BCL7A, and BCL2L11 in the BCL-family translocation group detected in endometrial carcinoma. PMID:23636398

Therapeutic relevance

  • BCL9 is an emerging therapeutic target in Wnt-driven malignancies; relevance of BCL9 translocations in endometrial carcinoma to Wnt pathway activation or drug response has not been tested. PMID:23636398

Open questions

  • Individual fusion partners and functional oncogenic impact of BCL9 translocations in endometrial carcinoma require experimental validation. PMID:23636398

Sources

This page was processed by crosslinker on 2026-05-09.